Details for Patent: 9,259,423

Which drugs does patent 9,259,423 protect, and when does it expire?

Patent 9,259,423 protects LATUDA and is included in one NDA.

Protection for LATUDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in five countries.

Summary for Patent: 9,259,423

Patent landscape, scope, and claims:

Title:	Method of treatment for mental disorders
Abstract:	The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D.sub.4 receptor agonist.
Inventor(s):	Ikeda; Kazuhito (Osaka, JP), Ishiyama; Takeo (Osaka, JP)
Assignee:	Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)
Application Number:	13/555,044
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,259,423
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,259,423

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-003	Dec 7, 2011	AB	RX	Yes	No					Y
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-001	Oct 28, 2010	AB	RX	Yes	Yes					Y
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-005	Jul 12, 2013	AB	RX	Yes	No					Y
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-002	Oct 28, 2010	AB	RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 9,259,423

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2011-033453	Feb 18, 2011

International Family Members for US Patent 9,259,423

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2814828
China	103180315
European Patent Office	2638038
Japan	2013541582